Vaccine Development, Its Implementation and Price Setting: A Historical Perspective with Proposed Ways to Move Forward.
Saved in:
| Title: | Vaccine Development, Its Implementation and Price Setting: A Historical Perspective with Proposed Ways to Move Forward. |
|---|---|
| Authors: | Standaert, Baudouin, Topachevskyi, Oleksandr, Ethgen, Olivier |
| Source: | Journal of Market Access & Health Policy; Dec2025, Vol. 13 Issue 4, p50, 14p |
| Abstract: | Vaccination has resulted in substantial public health benefits for human populations worldwide since it was first introduced more than a century ago. This article presents an overview of the history of vaccine development, its implementation, and price setting, the latter mainly from a developed world perspective. It considers potential issues and challenges. Over time, vaccine development and production has evolved to a market-driven approach, conducted largely by private commercial entities. The complex processes of identifying potential vaccine targets and developing and producing vaccines at scale have now become more efficient. However, vaccine pricing is an emerging concern. The elements that maximize the overall health benefit of vaccination include high volume, high coverage, and rapid initial implementation to achieve the high coverage with the vaccine as quickly as possible. It therefore requires substantial initial investment. Consequently, the price set for the vaccine should be reasonable to avoid limiting the coverage given the available budget. Suboptimal coverage leads to suboptimal benefit if herd protection is not fully achieved. This may disappoint health authorities and may result in program discontinuation. Conventional cost-effectiveness analysis is therefore not ideally suited to vaccine price setting, as it is based on the concept of 'more for more', i.e., higher health gain achieved at a higher reimbursement cost that does not account for limited budgets. Constrained optimization (CO) combines value assessment with constrained budget allocation into one analysis method and may therefore be the better option for vaccine pricing. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Market Access & Health Policy is the property of MDPI and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Biomedical Index |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science Be the first to leave a comment!